Policies for Prevention and Treatment of Hypertension

2003 ◽  
pp. 389-400
Keyword(s):  
Prevention And Treatment ◽  
Treatment Of Hypertension

scholarly journals Blood Pressure Targets for Older Patients—Do Advanced Age and Frailty Really Not Matter?

2020 ◽  
Vol 23 (2) ◽  
pp. 205-209
Author(s):  
Amanda Giffin ◽  
Kenneth M. Madden ◽  
David B. Hogan
Keyword(s):  
Blood Pressure ◽  
Risk Assessment ◽  
Older Patients ◽  
Intensive Therapy ◽  
Advanced Age ◽  
Blood Pressure Targets ◽  
Prevention And Treatment ◽  
Treatment Of Hypertension ◽  
The Relationship

In 2017, Hypertension Canada removed advanced age and frailty as considerations for caution when deciding on intensive therapy in their guidelines for the diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Dementia is not mentioned. In this commentary, we review why advanced age and frailty were removed, and examine what is currently known about the relationship between hypertension and both incident and prevalent dementia. We make the case that the presence of frailty (especially when severe) and dementia should be considered when deciding on intensive therapy in future iterations of Hypertension Canada guidelines.

Weight Reduction in the Prevention and Treatment of Hypertension: A Review of Representative Clinical Trials

1991 ◽  
Vol 5 (3) ◽  
pp. 208-214 ◽  
Author(s):  
Sheila A. Corrigan ◽  
James M. Raczynski ◽  
Charles Swencionis ◽  
Stephanie G. Jennings
Keyword(s):  
Clinical Trials ◽  
Weight Reduction ◽  
Prevention And Treatment ◽  
Treatment Of Hypertension

scholarly journals Internet-based patient– primary care physician–cardiologist integrated management model of hypertension in China: study protocol for a multicentre randomised controlled trial

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e039447
Author(s):  
Runyu Ye ◽  
Rufeng Shi ◽  
Kai Liu ◽  
Xin Zhang ◽  
Si Wang ◽  
...  
Keyword(s):  
Primary Care ◽  
Randomised Controlled Trial ◽  
Primary Care Physicians ◽  
Integrated Management ◽  
Controlled Trial ◽  
Care Physician ◽  
Management Model ◽  
Prevention And Treatment ◽  
Treatment Of Hypertension ◽  
Randomised Controlled

IntroductionThe control rate of hypertension is low in China, especially in rural, western and minority areas. This is related to poor medical skills among physicians in primary care institutions and low levels of trust among patients. However, primary healthcare institutions are the main battleground for the prevention and treatment of hypertension. It is worth exploring how to most effectively integrate patients, primary care physicians and cardiologists in tertiary hospitals, to build a long-term mechanism for the prevention and treatment of hypertension. In this study, we aim to evaluate the clinical effectiveness and conduct a health economic evaluation of an internet-based patient–primary care physician–cardiologist integrated management model of hypertension in areas of China with different socioeconomic levels.Methods and analysisThis is a 12-month, multicentre, randomised controlled trial involving patients with hypertension in urban communities and rural areas of Sichuan Province, China. Each primary healthcare institution will cooperate with their tertiary hospital through the Red Shine Chronic Disease Management System (RSCDMS). Patients will be randomly assigned 1:1 to two groups: (1) a traditional care group; (2) an intervention group in which primary care physicians and cardiologists can share patient data and manage patients together through the RSCDMS. Patients can upload their blood pressure (BP) values and communicate with physicians using the system. The primary outcome is the change in systolic BP over a 12-month period. Secondary outcomes are changes in diastolic BP, BP control rate, values of 24-hour ambulatory BP monitoring, difference in cost-effectiveness between the groups, patient satisfaction, medication adherence and home BP monitoring compliance. All data will be recorded and stored in the RSCDMS and analysed using IBM SPSS V.26.0.Ethics and disseminationThis study has been approved by the Biomedical Research Ethics Committee of the West China Hospital of Sichuan University in Sichuan, China (No. 2020-148). Written informed consent will be obtained from all participants. The results of this study will be disseminated to the public through academic conferences and peer-reviewed journals.Trial registration numberChiCTR2000030677.

Depression Rises the Risk of Hypertension Incidence: Discussing the Link through the Ca2+/cAMP Signalling

2020 ◽  
Vol 16 (1) ◽  
pp. 73-78
Author(s):  
Leandro B. Bergantin
Keyword(s):  
Signalling Pathways ◽  
Cellular Mechanisms ◽  
Medical Problems ◽  
Camp Signalling ◽  
Data Support ◽  
High Prevalence ◽  
The World ◽  
Prevention And Treatment ◽  
Treatment Of Hypertension ◽  
Risk Issue

Background: Depression and hypertension are medical problems both with clearly restricted pharmacotherapies, along with a high prevalence around the world. In fact, an intensive discussion in the field is that a dysregulation of the intracellular Ca2+ homeostasis (e.g. excess of intracellular Ca2+) contributes to the pathogenesis of both hypertension and depression. Furthermore, depression rises the risk of hypertension incidence. Indeed, several data support the concept that depression is an independent risk issue for hypertension. Conclusion: Then, which are the possible cellular mechanisms involved in this link between depression and hypertension? Considering our previous reports about the Ca2+ and cAMP signalling pathways (Ca2+/cAMP signalling), in this review I have discussed the virtual involvement of the Ca2+/cAMP signalling in this link (between depression and hypertension). Then, it is important to consider depression into account during the process of prevention, and treatment, of hypertension.

Sign in / Sign up

Export Citation Format

Share Document